Prof. Dr. Ernesto Maddaloni

Department of Experimental Medicine, Unit of Diabetes, Sapienza University of Rome, Rome, Italy

Dr Maddaloni gained his MD, clinical specialty in Endocrinology and Diabetes and PhD in “Integrated Biomedical Sciences and Bioethics” at Campus Bio-Medico University of Rome. He has joined the Vascular Cell Biology Section of the Joslin Diabetes Center (Harvard Medical School, Boston, MA, USA) for a Research Fellowship in 2014. Back in Italy, since 2018 he has been employed at the Department of Experimental Medicine, Unit of Diabetes, Sapienza University of Rome, where he is currently Associate Professor of Endocrinology and Diabetes. He also holds a position as Research Associate at the Diabetes Trial Unit, University of Oxford, UK, which he joined in in 2017 as a mentee of the European Foundation for the Study of Diabetes (EFSD) Future Leaders Mentorship Program.
Dr Maddaloni actively pursue studies on clinical diabetes, cardiovascular outcomes and novel diabetes complications. His research interests focus on the study of adults with autoimmune diabetes and the interplay between vascular complications, bone health and autoimmunity. After the Sars-CoV2 infection outbreak, he has contributed also with original articles evaluating the strict relationship between diabetes and related comorbidities with Covid-19.
Dr Maddaloni has been a study investigator and coordinator for several national and international clinical trials and has published as lead author in several top-ranked peer-reviewed international medical journals.
His scientific achievements have been recognized with several awards, including the 2015 Albert Renold Fellowship from the European Foundation for the Study of Diabetes, the 2017 (under 32) and 2021 (under 35) Young Investigator Awards from the Italian Society of Endocrinology (SIE), the 2017 Early Investigator Award from the Endocrine Society (USA) and the 2020 Young (under 35) Investigator Award and the Alcmeone award from the Italian Society of Diabetes (SID).

Updated 30 October 2024